News

Glenmark Pharmaceuticals has launched Tiogiva, a tiotropium bromide dry powder inhaler (DPI) for the treatment of chronic obstructive pulmonary disease (COPD), in the U.K. Tiogiva is the bioequivalent generic version of Boehringer Ingelheim’s…

Although lung cancer development is unpredictable, patients with chronic obstructive pulmonary disease (COPD) appear more likely to have the cancer and a worse prognosis compared with the general population, a Japanese study has found. Annual computed tomography (CT) screens may help with the early detection and treatment of this…

TrialSpark, a technology company that helps streamline the clinical trial process, has partnered with global biopharmaceutical company Sanofi to conduct clinical studies and accelerate the development of new treatments for chronic obstructive pulmonary disease (COPD). TrialSpark’s system is expected to improve the enrollment of Black and Hispanic COPD…

Medical Mutual of Ohio now covers Spiration Valve System (SVS), Olympus‘ minimally invasive therapy for eligible patients with severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD). “This decision by Medical Mutual will provide expanded access to this critical therapy that significantly reduces lung hyperinflation associated with…

The National Heart, Lung, and Blood Institute awarded $962,000 to a University of Buffalo researcher to develop risk models that help to improve patient care and lower hospital readmission rates for people with chronic obstructive pulmonary disease (COPD). “Each year, 7.8 million hospital-discharged patients are readmitted, costing the United…

The Zephyr Endobronchial Valve significantly improved lung function and quality of life for at least two years in people with emphysema, a severe form of chronic obstructive pulmonary disease (COPD), according to new clinical trial data. “These long-term data further demonstrate that our Zephyr Valve is a safe,…

Approximately 40% of chronic obstructive pulmonary disease (COPD) patients in the U.S. — and notably, most of those living in small towns or rural areas — have limited access to pulmonary rehabilitation (PR) maintenance programs, according to a recent study. Indeed, roughly 17% of people with COPD from this…

Note: This story was updated May 21, 2021, as an earlier version of this article misidentified Renu Jain, PhD, scientific director of medical affairs at GlaxoSmithKline.  People with chronic obstructive pulmonary disease (COPD) who do not experience exacerbations, or flare-ups, within the previous 12 months are still at risk…

Scientists have identified several genes associated with rapid lung function decline in former and current smokers that might help identify people who are most at risk of developing smoking-related conditions like chronic obstructive pulmonary disorder (COPD). These genes could also improve future clinical trials by helping to identify patients…

Enrollment is now concluded in a clinical trial evaluating the mechanism of action of RejuvenAir Metered Cryospray, an investigational treatment for chronic bronchitis, the most common form of chronic obstructive pulmonary disease (COPD). Chronic bronchitis is long-term inflammation of the airways, characterized by coughing and excessive mucus production.